2LB Phase III, randomized, open-label, parallel-group study of oral gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who have previously received platinum- based chemotherapy (INTEREST)
Jean‐Yves Douillard, E.S. Kim, Vera Hirsh et al. · European Journal of Cancer Supplements · 2007
Cited by 14 works. doi:10.1016/s1359-6349(07)70095-2